Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOPPatrizia Pregno, Umberto Vitolo, Annalisa Chiappella et al.|Blood|2012Cited by 238
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA studyGiuseppe Rossi, Wilma Barcellini, Francesca Romana Mauro et al.|Blood|2018Cited by 89
Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.Patrizia Pregno, Umberto Vitolo, Annalisa Chiappella et al.|Blood|2009Cited by 12
The Outcome of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP (R-CHOP) Is Not Predicted by 18-FDG-Positron Emission Tomography/Computerized Tomography (PET) Performed at Intermediate In-Course Evaluation, but Only by PET Assessed at the End of Therapy.Umberto Vitolo, G Bisi, Annalisa Chiappella et al.|Blood|2010Cited by 4